A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Sponsored by Enliven Therapeutics
About this trial
Last updated 2 years ago
Study ID
ELVN-001-101
Status
Recruiting
Type
Interventional
Phase
Phase 1
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 3 years ago
What is this trial about?
The purpose of this study is to evaluate the safety, tolerability and determine the
recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid
leukemia with and without T315I mutations in patients who are relapsed, refractory or
intolerant to TKIs.
What are the participation requirements?
Inclusion Criteria
- CML that has failed or the patient is intolerant to available therapies known to be active for treatment of their CML.
- ECOG performance status of 0 to 2.
- Adequate hematologic, hepatic and renal function.
Exclusion Criteria
- Treatment with anti-cancer or anti-CML therapy within 7 days or 5 half-lives, whichever is longer.
- QTc >470 ms.
Locations
Location
Status
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Not yet recruiting